196 related articles for article (PubMed ID: 20640858)
1. Diagnostic utility of immunohistochemical panel in various thyroid pathologies.
Ozolins A; Narbuts Z; Strumfa I; Volanska G; Gardovskis J
Langenbecks Arch Surg; 2010 Sep; 395(7):885-91. PubMed ID: 20640858
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules.
Ozolins A; Narbuts Z; Strumfa I; Volanska G; Stepanovs K; Gardovskis J
Medicina (Kaunas); 2012; 48(10):507-14. PubMed ID: 23324246
[TBL] [Abstract][Full Text] [Related]
3. The Role of CD56 in Thyroid Fine Needle Aspiration Cytology: A Pilot Study Performed on Liquid Based Cytology.
Bizzarro T; Martini M; Marrocco C; D'Amato D; Traini E; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM; Rossi ED
PLoS One; 2015; 10(7):e0132939. PubMed ID: 26186733
[TBL] [Abstract][Full Text] [Related]
4. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
5. Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility.
Skaria PE; Ahmed AA; Yin H; Nicol K; Reid KJ; Singh V
Pathol Res Pract; 2019 May; 215(5):880-884. PubMed ID: 30711197
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential.
Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A
Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165
[TBL] [Abstract][Full Text] [Related]
7. CD56 expression in benign and malignant thyroid lesions.
Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
[TBL] [Abstract][Full Text] [Related]
8. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
9. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.
Saleh HA; Jin B; Barnwell J; Alzohaili O
Diagn Pathol; 2010 Jan; 5():9. PubMed ID: 20181018
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
11. Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.
Elsers DA; Hussein MRA; Osman MH; Mohamed GA; Hosny G
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3365-3376. PubMed ID: 34711014
[TBL] [Abstract][Full Text] [Related]
12. Is BECLIN-1 Immunoreactivity More Effective than HBME-1 in Diagnosis of Papillary Thyroid Cancer?
Yeşil C; Kandemir O; Haksever H; Dabakoğlu T
Acta Chir Belg; 2015; 115(4):299-305. PubMed ID: 26324033
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules.
Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS
Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma.
Yang X; Hu Y; Shi H; Zhang C; Wang Z; Liu X; Chen H; Zhang L; Cui D
Eur Arch Otorhinolaryngol; 2018 Aug; 275(8):2127-2134. PubMed ID: 29951933
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
16. Thyroid tumors of uncertain malignant potential: morphologic and imunohistochemical analysis of 29 cases.
Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Cătană R; Borson-Chazot F; Berger N; Decaussin-Petrucci M
Pathol Res Pract; 2015 Apr; 211(4):320-5. PubMed ID: 25595997
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
18. Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the Ki-67 proliferative index in addition to cytokeratin-19 and HBME-1 immunomarkers: a study of 61 cases of liquid-based FNA cytology with histological controls.
Lacoste-Collin L; d'Aure D; Bérard E; Rouquette I; Delisle MB; Courtade-Saïdi M
Cytopathology; 2014 Jun; 25(3):160-9. PubMed ID: 24460983
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the diagnostic value of emerin and CD56 in papillary thyroid carcinoma - an immunohistochemical study.
Abdou AG; Abdelwahed M; Said A; Taie DM; Fahmy S
J Immunoassay Immunochem; 2018; 39(5):521-537. PubMed ID: 30188764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]